These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25407235)

  • 1. Correspondence.
    Primavera V; Querques G
    Retina; 2014 Dec; 34(12):e39-40. PubMed ID: 25407235
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply: To PMID 23881226.
    Stalmans P; Duker JS
    Retina; 2015 Apr; 35(4):e28-9. PubMed ID: 25807179
    [No Abstract]   [Full Text] [Related]  

  • 3. Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis.
    Stalmans P; Duker JS; Kaiser PK; Heier JS; Dugel PU; Gandorfer A; Sebag J; Haller JA
    Retina; 2013; 33(10):2003-11. PubMed ID: 23881226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knowledge of vitreomacular traction (VMT) scenarios: Is doing nothing still a beneficial alternative and, if so, when?
    Ziemssen F; Bartz-Schmidt KU; Dimopoulos S
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):615-6. PubMed ID: 26887826
    [No Abstract]   [Full Text] [Related]  

  • 5. [Non-surgical treatment of vitreomacular traction and macular hole].
    Arias Barquet L
    Arch Soc Esp Oftalmol; 2013 Dec; 88(12):455-7. PubMed ID: 24257254
    [No Abstract]   [Full Text] [Related]  

  • 6. Ocriplasmin-Induced Macular Hole Closure in the Absence of Vitreomacular Adhesion Release.
    Modi YS; Singh RP
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):677-9. PubMed ID: 26114851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocriplasmin: nonsurgical option for VMA and macular hole, but with potential barriers to practical use.
    Ober MD; Hariprasad SM
    Ophthalmic Surg Lasers Imaging Retina; 2013; 44(2):113-6; discussion p.113. PubMed ID: 23510035
    [No Abstract]   [Full Text] [Related]  

  • 8. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
    Hong J; Deng SX; Xu J
    N Engl J Med; 2012 Nov; 367(21):2053; author reply 2054. PubMed ID: 23171110
    [No Abstract]   [Full Text] [Related]  

  • 9. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
    Rao RC; Dlouhy BJ
    N Engl J Med; 2012 Nov; 367(21):2053; author reply 2054. PubMed ID: 23171109
    [No Abstract]   [Full Text] [Related]  

  • 10. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
    Huang J; Wen D; Wang Q
    N Engl J Med; 2012 Nov; 367(21):2052-3; author reply 2054. PubMed ID: 23171108
    [No Abstract]   [Full Text] [Related]  

  • 11. Novel possibility of vitreomacular traction treatment.
    Michalska-Małecka K; Witek K; Sierocka-Stępień J; Wyględowska-Promieńska D; Nowak M
    Acta Ophthalmol; 2016 Dec; 94(8):e818-e819. PubMed ID: 27167161
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.
    Chatziralli I; Theodossiadis G; Parikakis E; Datseris I; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):223-33. PubMed ID: 25940555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of vitreomacular interface disease in patients presenting to a tertiary care institution.
    Xu LT; Punjabi OS; Shao J; Ehlers JP; Srivastava SK; Singh RP; Kaiser PK
    Ophthalmic Surg Lasers Imaging Retina; 2014; 45(6):517-20. PubMed ID: 25423630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole.
    Gandorfer A; Benz MS; Haller JA; Stalmans P; Pakola SJ; Girach A; Kampik A; Toth CA; Jaffe GJ;
    Retina; 2015 Jun; 35(6):1151-7. PubMed ID: 25741816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How should we release vitreomacular traction: surgically, pharmacologically, or pneumatically?
    Johnson MW
    Am J Ophthalmol; 2013 Feb; 155(2):203-205.e1. PubMed ID: 23312439
    [No Abstract]   [Full Text] [Related]  

  • 16. Initial experience with ocriplasmin in the treatment of vitreomacular traction.
    Garcia JM; Isaac DL; Ávila M
    Arq Bras Oftalmol; 2016 Apr; 79(2):85-7. PubMed ID: 27224069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Serous Macular Detachments and Visual Disturbance Complicating Consecutive Cases of Symptomatic Vitreomacular Adhesion With Macular Hole Treated With Ocriplasmin.
    Luttrull JK
    Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):976-8. PubMed ID: 26469240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reopening of a Full-Thickness Macular Hole 2 Years After Pharmacologic Closure With Ocriplasmin.
    Khan MA; Shahlaee A; Ho AC
    JAMA Ophthalmol; 2015 Nov; 133(11):1362-4. PubMed ID: 26379104
    [No Abstract]   [Full Text] [Related]  

  • 19. Functional improvement assessed by multifocal electroretinogram after Ocriplasmin treatment for vitreomacular traction.
    Rossi S; Testa F; Melillo P; Orrico A; Della Corte M; Simonelli F
    BMC Ophthalmol; 2016 Jul; 16():110. PubMed ID: 27430356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome.
    Singh RP; Li A; Bedi R; Srivastava S; Sears JE; Ehlers JP; Schachat AP; Kaiser PK
    Br J Ophthalmol; 2014 Mar; 98(3):356-60. PubMed ID: 24357495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.